MedPath

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00000803
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To determine the safety and anti-HIV activity of delavirdine mesylate ( U-90152 ) in combination with zidovudine ( AZT ) and/or didanosine ( ddI ) versus AZT/ddI combination.

U-90152 has demonstrated anti-HIV activity. Since the combination of this drug with either AZT or ddI has synergistic inhibitory activity against HIV-1 in vitro, and triple therapy appears to have greater inhibitory activity against HIV-1 in vitro than dual therapy, the use of U-90152 in combination with AZT and/or ddI may improve the benefits of these drugs in persons with HIV disease.

Detailed Description

U-90152 has demonstrated anti-HIV activity. Since the combination of this drug with either AZT or ddI has synergistic inhibitory activity against HIV-1 in vitro, and triple therapy appears to have greater inhibitory activity against HIV-1 in vitro than dual therapy, the use of U-90152 in combination with AZT and/or ddI may improve the benefits of these drugs in persons with HIV disease.

Patients are randomized to receive U-90152/AZT/ddI, U-90152/AZT, U-90152/ddI, or AZT/ddI for 48 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
471
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (32)

Alabama Therapeutics CRS

🇺🇸

Birmingham, Alabama, United States

USC CRS

🇺🇸

Los Angeles, California, United States

Stanford CRS

🇺🇸

Palo Alto, California, United States

Ucsd, Avrc Crs

🇺🇸

San Diego, California, United States

Ucsf Aids Crs

🇺🇸

San Francisco, California, United States

University of Colorado Hospital CRS

🇺🇸

Aurora, Colorado, United States

Howard University Hosp., Div. of Infectious Diseases, ACTU

🇺🇸

Washington, District of Columbia, United States

Univ. of Miami AIDS CRS

🇺🇸

Miami, Florida, United States

Queens Med. Ctr.

🇺🇸

Honolulu, Hawaii, United States

Univ. of Hawaii at Manoa, Leahi Hosp.

🇺🇸

Honolulu, Hawaii, United States

Scroll for more (22 remaining)
Alabama Therapeutics CRS
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.